LDL-lowering study for adults with type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study looks at cholesterol lowering in adults with type 1 diabetes and whether it reduces “residual risk,” meaning risk that may remain even with current care. You may be asked to take cholesterol-focused treatment and complete blood tests to track LDL (“bad cholesterol”).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 1 diabetes for at least 1 year
- You are 18 to under 90 years old
- Your LDL (“bad cholesterol”) is higher than 100 mg/dL
- You can sign written consent to join the study
- You do not have triglycerides higher than 400 mg/dL
- You are not currently using a PCSK9 inhibitor or antithrombotic medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
This study measures how “blood fats” move in the body after fasting and controlled eating, comparing people with type 1 diabetes to those without diabetes. It may help researchers understand diabetes-related differences in lipid (fat) handling and improve future treatments.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
This study is looking for adults with type 1 diabetes to help improve guidelines for preventing and treating low blood sugar (hypoglycemia). The goal is to make recommendations that are more practical and safer for people like you.
This study offers a structured education course and regular checkups to help adults with type 1 diabetes better manage their blood sugar and overall health. Participants will learn about their condition and receive support to improve metabolic indicators.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.